Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

NCT03031938 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis
Cancer Pain
Recurrent Low Back Pain

Interventions

DRUG: Investigational medical product (IMP) administered in parent study

Sponsor

Pfizer

Collaborators

[object Object]